Drug Trial Radar · NCT05234580
Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Apr 15, 2022
Primary completion
Oct 10, 2022
Study completion Dec 25, 2022
Sponsor
- Lead sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.
Conditions
- Allergic Rhinitis
Interventions
PA9159 nasal spray solution, 10 μg once daily for 14 daysDrug
PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
PA9159 nasal spray solution, 20 μg once daily for 14 daysDrug
PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
PA9159 nasal spray solution, 40 μg once daily for 14 daysDrug
PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Placebo nasal spray solution without PA9159, once daily for 14 daysDrug
Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation the change from baseline in daily subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) averaged over the 14-day treatment period.Time frame: From pre-dose until 14 days post-dose
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Beijing TongRen Hospital
Beijing, Beijing Municipality, China
Dongfang Hospital Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
The Affiliated Hospital of Changchun University of Chinese Medicine
Changchun, Jilin, China
Tonghua Central Hospital
Tonghua, Jilin, China
Yanbian University Hospital(Yanbian Hospital)
Yanji, Jilin, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Zibo Central Hospital
Zibo, Shandong, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.